Ultragenyx Pharmaceutical

Novato, California biopharmaceutical company founded in 2010, built specifically around rare and ultra-rare genetic diseases; FAYUVI is its first approved gene therapy for a neurodegenerative disease of childhood.

ultragenyx.com

2 stories

Regulatory News has published 2 stories about Ultragenyx Pharmaceutical between 18 September 2026 and 28 September 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 28 September 2026.

This page is generated from Regulatory News’ editorial coverage of Ultragenyx Pharmaceutical. It is not an advertisement.

Products in our coverage

FAYUVIrebisufligene etisparvovec-hopf

Our coverage

2 stories, newest first.

A professional in a white blouse signs and stamps documents at a desk beside a laptop

For Physicians FAYUVI's Label Limits It to Early-Stage Sanfilippo Sep 28, 20268 min read Read the story

A researcher wearing safety glasses and a white lab coat looks through a microscope eyepiece while adjusting a sample slide

Drugs & Biologics FDA Approves First Gene Therapy for Sanfilippo Type A Sep 18, 20265 min read Read the story

All companies